- Alopecia areata. [Letter]
- JAJ Am Acad Dermatol 2018; 79(1):e9-e10
- Ichthyosis, atopic dermatitis, and alopecia. [Journal Article]
- IJInt J Dermatol 2018 Jun 15
- The ethical issue of "cherry picking" patients. [Journal Article]
- JAJ Am Acad Dermatol 2018 Jun 12
- Platelet rich plasma for the management of hair loss: Better alone or in combination? [Journal Article]
- JCJ Cosmet Dermatol 2018 Jun 14
- Platelet-rich plasma (PRP) and autologous protein-based treatments have recently emerged as a potential therapeutic approach for hair loss-related disorders including androgenetic alopecia and alopec...
Platelet-rich plasma (PRP) and autologous protein-based treatments have recently emerged as a potential therapeutic approach for hair loss-related disorders including androgenetic alopecia and alopecia areata. The safety and efficacy of repeated intradermal injections of PRP has proved to promote hair growth in a number of randomized clinical trials. Biologically active proteins and cytokines released upon platelet activation have shown to induce folliculogenesis and activate the anagen growing phase of dormant bulbs. Interestingly, further studies have revealed that combining PRP with other hair loss-related products may enhance the final performance of the treatment. These synergistic approaches include Food and Drug Administration (FDA) approved drugs such as finasteride or minoxidil, bioactive macromolecules and cell-based therapies. Here, recent research involving alone or combined therapy with platelet-rich plasma for the management of hair loss-related disorders are outlined and future prospects are discussed.
- Depression of the Frontal Veins in Frontal Fibrosing Alopecia. [Journal Article]
- ADActas Dermosifiliogr 2018 Jun 11
- Frontal fibrosing alopecia: Regrowth following cessation of sunscreen on the forehead. [Letter]
- AJAustralas J Dermatol 2018 Jun 12
- Characterization of Heterozygous HTRA1 Mutations in Taiwanese Patients With Cerebral Small Vessel Disease. [Journal Article]
- SStroke 2018 Jun 12
- CONCLUSIONS: Heterozygous HTRA1 mutations account for 2.08% (7 of 337) of SVD in Taiwan. The clinical and neuroradiological features of HTRA1-related SVD and sporadic SVD are similar. These findings broaden the mutational spectrum of HTRA1 and highlight the pathogenic role of heterozygous HTRA1 mutations in SVD.
- IgG4-related disease presenting with scarring alopecia of the scalp. [Journal Article]
- JCJAAD Case Rep 2018; 4(6):555-557
- Cicatricial Alopecia in Identical Twin Lumbee Native American Women. [Journal Article]
- SASkin Appendage Disord 2018; 4(2):108-111
- Central centrifugal cicatricial alopecia (CCCA) has become a well-known entity occurring mainly in African-American women, but is rarely encountered in other populations. This report describes a set ...
Central centrifugal cicatricial alopecia (CCCA) has become a well-known entity occurring mainly in African-American women, but is rarely encountered in other populations. This report describes a set of identical twin Lumbee Indian women, both developing cicatricial alopecia, with one sister diagnosed with CCCA overlap with lichen planopilaris and the other with CCCA. The Lumbee Tribe is a federally recognized group of Native Americans who reside in North Carolina. Lumbee Indians have shown an increased incidence of several metabolic and neurologic diseases but cicatricial alopecia has never been an identified associated disease of the Lumbee. Thus far, no published studies have shown cicatricial alopecia as occurring in identical twins or in Native Americans. This case report discusses the issues of haircare practices and genetics in contributing to cicatricial alopecia.
New Search Next
- Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. [Journal Article]
- BCBreast Care (Basel) 2018; 13(2):121-125
- CONCLUSIONS: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.